Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Eli Lilly Cancer Drug Misses The Mark In Critical Study

By Meagan Parrish | October 10, 2017

Eli Lilly reported disappointing results from a late-stage test of one of its cancer drugs.

According to Reuters, the pharmaceutical giant was testing a drug called Verzenio on patients with lung cancer. Verzenio was approved by the U.S. Food and Drug Administration earlier this year for patients with HR-positive, HER2-negative breast cancer. But the treatment — a daily CDK 4/6 inhibitor that blocks certain enzymes that promote the growth of cancer cells — failed to improve the overall survival rate in patients with small-cell lung cancer with a mutation of the KRAS gene.

The drug, however, did achieve secondary goals by showing evidence of providing a progression-free survival and an overall response rate.

“While the outcome is unfortunate for patients with KRAS-mutated, advanced lung cancer, we remain encouraged by the antitumor activity observed with abemaciclib in this form of lung cancer where few clinical advances have been achieved,” Levi Garraway, senior vice president of global development and medical affairs, said. 

The news is just the latest clinical trial setback for Lilly, which has already laid off nearly 9 percent of its workforce — or 3,500 positions — this year to save $500 million.

Last November, a potential Alzheimer’s treatment failed during a late-stage study.

The company has also seen sales fall in recent years as patent protections for two of its best-selling drugs — Cymbalta and Zyprexa — have been removed.

In April, the FDA also rejected a rheumatoid arthritis drug developed by Lilly.

Upon news of the Verzenio failure, Lilly’s stocks sank 4 percent.


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE